NCT03682770 - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

October 16, 2020

Study Completion Date

July 23, 2021

Conditions

Peanut Allergy

Interventions

DRUG

Dupilumab

Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)

DRUG

Placebo matching dupilumab

Placebo matching dupilumab is prepared in the same formulation without the addition of protein

DRUG

AR101

AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase

Trial Locations (25)

10029

Regeneron Investigational Site, New York

11021

Regeneron Investigational Site, Great Neck

19104

Regeneron Investigational Site, Philadelphia

20010

Regeneron Investigational Site, Washington D.C.

21287

Regeneron Investigational Site, Baltimore

27599

Regeneron Investigational Site, Chapel Hill

30144

Regeneron Investigational Site, Marietta

30329

Regeneron Investigational Site, Atlanta

33612

Regeneron Investigational Site, Tampa

35209

Regeneron Investigational Site, Birmingham

48106

Regeneron Investigational Site, Ann Arbor

48197

Regeneron Investigational Site, Ypsilanti

55402

Regeneron Investigational Site, Minneapolis

60611

Regeneron Investigational Site, Chicago

72202

Regeneron Investigational Site, Little Rock

80206

Regeneron Investigational Site, Denver

85724

Regeneron Investigational Site, Tucson

90027

Regeneron Investigational Site, Los Angeles

90095

Regeneron Investigational Site, Los Angeles

90274

Regeneron Investigational Site, Rolling Hills Estates

92691

Regeneron Investigational Site, Mission Viejo

94040

Regeneron Investigational Site, Mountain View

98115

Regeneron Investigational Site, Seattle

02114

Regeneron Investigational Site, Boston

07712

Regeneron Investigational Site, Ocean Township